Paliperidone palmitate vs paliperidone ER in acute schizophrenia: systematic review and network meta-analysis

Kishi T, Sakuma K, Iwata N. Transl Psychiatry. 2022;12:519.

Comparative pharmacology of risperidone and paliperidone

Corena-McLeod M. Drugs R D. 2015;15:163–174.

Paliperidone to Treat Psychotic Disorders

Minwalla HD, Wrzesinski P, Desforges A, et al. Neurol Int. 2021;13:343–358.

Efficacy and safety profile of paliperidone palmitate injections in schizophrenia: evidence-based review

Emsley R, Kilian S. Neuropsychiatr Dis Treat. 2018;14:205–223.

Paliperidone 3‑Month Injection for Treatment of Schizophrenia: A Narrative Review

Edinoff AN, Doppalapudi PK, Orellana C, et al. Front Psychiatry. 2021;12:699748.

Paliperidone for the treatment of schizoaffective disorder

Alphs L, Fu D-J, Turkoz I. Expert Opin Pharmacother. 2016;17(6):871–883.

How loading dose strategies for depot paliperidone can go wrong

Preskorn SH. J Psychiatr Pract. 2022;28(2):130–137.

Invega Hafyera (PP6M): Extended‑release injectable for schizophrenia

Peters L, Dyer M, Schroeder E, D’Souza MS. J Pharm Technol. 2023;39(2):88–94.

Efficacy and tolerability of paliperidone in mania of bipolar disorder: a meta-analysis

Chang H-Y, Tseng P-T, Stubbs B, et al. Exp Clin Psychopharmacol. 2017;25(5):422–433.

Cumulative clinical experience with paliperidone palmitate 3‑monthly (PP3M): critical appraisal

García-Carmona JA, Pappa S. Drug Healthc Patient Saf. 2023;15:113–123.

Critical appraisal of 3‑monthly paliperidone depot injections

Carpiniello B, Pinna F. Drug Des Devel Ther. 2016;10:1731–1742.

The current data on the 3‑month paliperidone palmitate formulation (PP3M)

Bioque M, Bernardo M. Expert Opin Pharmacother. 2018;19(14):1623–1629.

Role of paliperidone palmitate 3‑monthly in clinical practice

Lopez A, Rey J. Neuropsychiatr Dis Treat. 2019;15:449–456.

Clinical relevance of paliperidone palmitate 3‑monthly (PP3M)

Mathews M, Gopal S, Nuamah I, et al. Neuropsychiatr Dis Treat. 2019;15:1365–1379.